Gd-AAZTA-MADEC

an MRI blood-pool contrast agent; structure in first source

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

1.	Consolino, Lorena: 2 articles (01/2021 - 01/2016)
2.	Longo, Dario Livio: 2 articles (01/2021 - 01/2016)
3.	Anemone, Annasofia: 1 article (01/2021)
4.	Irrera, Pietro: 1 article (01/2021)
5.	Romdhane, Feriel: 1 article (01/2021)
6.	Aime, Silvio: 1 article (01/2016)
7.	Arena, Francesca: 1 article (01/2016)
8.	Geninatti-Crich, Simonetta: 1 article (01/2016)
9.	Giovenzana, Giovanni Battista: 1 article (01/2016)
10.	Minazzi, Paolo: 1 article (01/2016)

1.	Neoplasms (Cancer) 01/01/2016 - "The herein reported pre-clinical imaging studies show that a great benefit arises from the combination of a benchtop MRI scanner operating at 1 T and the albumin-binding Gd-AAZTA-MADEC complex, for pursuing enhanced angiography and improved characterization of tumor vascular microenvironment." 01/01/2016 - "A novel MRI blood-pool contrast agent (Gd-AAZTA-MADEC) has been compared with established blood pool agents for tumor contrast enhanced images and angiography. " 01/01/2021 - "In tumors receiving both CEST and T1 -weighted agents, a voxel-by-voxel analysis indicated moderate spatial correlation of perfusion properties between voluven/dextran 70 and Gd-AAZTA-Madec, suggesting different distribution patterns according to their molecular size. " 01/01/2021 - "In vivo studies in a murine adenocarcinoma model (n = 4 mice for each contrast agent) upon i.v. injection provided CEST-derived perfusion tumor properties that were compared with those obtained with a gadolinium-based blood-pool agent (Gd-AAZTA-Madec). "
2.	Adenocarcinoma 01/01/2021 - "In vivo studies in a murine adenocarcinoma model (n = 4 mice for each contrast agent) upon i.v. injection provided CEST-derived perfusion tumor properties that were compared with those obtained with a gadolinium-based blood-pool agent (Gd-AAZTA-Madec). "